Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Finasteride

Brand: 
NICE TA: 
Indication: Benign prostatic hyperplasia
Disease category: Endocrine system
Commissioning responsibility: CCG
PbR excluded: No

Background

Finasteride is the preferred 1st line 5α-reductase inhibitor for Benign Prostatic Hyperplasia (BPH) within the Lancashire Health Economy. This is because:
• Finasteride is significantly less expensive than the alternative 5‑α reductase
inhibitor dutasteride.
• The Enlarged Prostate International Comparator Study (EPICS) found, when dutasteride or finasteride were administered for 12 months, they were similarly effective at 3 months and 12 months in reducing prostate volume, improving Qmax and urinary symptoms associated with BPH.
• Additionally the EPICS study also found no difference in overall numbers of adverse events between finasteride and dutasteride.

Recommendation

LMMG recommendation: Green
Click here to find the definitions for the colour classifications

Reason for decision:  Suitable for initiation in primary care

Supporting documents:

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Green

Green

Green